Understanding Fertility Options: Dr. Bana Kashani Offers Expert Insights During National Infertility Awareness Week
ALISO VIEJO, Calif.--(BUSINESS WIRE)--As more individuals delay starting a family, having accurate information and understanding fertility options is increasingly important for those trying to conceive now or planning for the future. In recognition of National Infertility Awareness Week (NIAW, April 20–26), a movement founded by RESOLVE: The National Infertility Association and supported by sponsors like First Response, Dr. Bana Kashani, M.D., OB-GYN, Reproductive Endocrinologist & Infertility Specialist, emphasizes the value of fertility education and proactive reproductive planning.
'Fertility isn't always a straightforward journey, and understanding your options early can make a meaningful difference,' says Dr. Kashani.
'Fertility isn't always a straightforward journey, and understanding your options early can make a meaningful difference,' says Dr. Kashani. 'Whether you're thinking about starting a family soon or just want to keep your options open for the future, being proactive about your reproductive health empowers you to make informed choices that align with your goals and lifestyle.'
Below, Dr. Kashani shares her expert insights on understanding fertility options and preservation, as well as how to effectively navigate conversations with healthcare providers.
What tests are available to understand fertility?
Fertility testing varies based on your needs. At-home tests help track ovulation and peak fertility days, while in-office tests can identify causes of infertility and guide treatment. For women, testing often includes checking hormone levels, ovarian reserve, and ultrasounds. For men, common tests include semen analysis, hormone tests, and testicular ultrasounds.
Do my lifestyle choices impact fertility?
Lifestyle factors such as diet, exercise, and stress can influence fertility by affecting hormone balance and egg and sperm quality. Eating a healthy, nutrient-rich diet supports reproductive health, while poor nutrition, along with excessive alcohol and caffeine intake, may lead to imbalances. Smoking and vaping can also harm fertility by affecting hormone levels and reproductive function. While moderate exercise is beneficial, excessive physical activity can disrupt ovulation or lower sperm quality. Additionally, high stress levels can affect hormone regulation and make it harder to conceive.
Does birth control affect fertility?
It's a common misconception that birth control can cause long-term fertility issues, when in reality, it doesn't permanently affect fertility. Hormonal birth control methods, like the pill, patch, or IUD, prevent ovulation and endometrial implantation, and once you stop using them, your fertility usually returns to normal within a few months. However, it can take longer for some people, especially after long-term use, as it may take time for your menstrual cycle to fully regulate.
What is the difference between IUI and IVF?
IUI (Intrauterine Insemination) involves directly inserting sperm into the uterus during ovulation and is commonly used for mild infertility issues like unexplained infertility or mild male factor problems. IVF (In-Vitro Fertilization) involves retrieving eggs, fertilizing them in a lab, culturing embryos in the lab and then transferring embryos into the uterus. IVF is typically used for more severe infertility issues, such as blocked fallopian tubes, significant male factor infertility or advanced maternal age and tends to have higher success rates than IUI.
At what age and under what circumstances should someone consider egg freezing?
Egg freezing is a viable option for women who want to preserve fertility for future use, particularly if they're not ready for children now but may want them later. The best time to freeze eggs is typically in the late 20s to early 30s, when egg quality and quantity are still high. It's also recommended for women facing medical treatments like chemotherapy, those with reproductive health issues, such as endometriosis or PCOS, or those with a family history of early menopause. Additionally, women who delay parenthood due to career or personal goals may consider egg freezing to keep their options open.
What advice do you have regarding navigating conversations about fertility with your healthcare provider?
Knowledge is power, so it's essential to do your research before talking to your healthcare provider and come prepared with questions. Take time to evaluate your fertility goals, including how many children you'd like and any ethical or personal preferences for treatments. It's also helpful to provide detailed information about your menstrual cycle, including any pain or irregularities that could point to an underlying condition. Lastly, consider discussing the option of meeting with a fertility specialist for a more detailed conversation and to complete preliminary fertility testing.
Dr. Kashani also encourages individuals to take advantage of the growing resources available for those navigating fertility.
'RESOLVE offers free support groups and other resources to empower people through every stage of their fertility journey. First Response also offers community support through The Pregnancy Hub, an online space designed to connect and inspire those navigating fertility and parenthood. Accessing these resources can help individuals feel less alone, make more informed decisions, and find emotional support during what can often be a complex and challenging time,' adds Dr. Kashani.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. WALTHAM, Mass. & GENEVA, Switzerland, June 10, 2025--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections and the World Health Organization (WHO) identifying antimicrobial resistance (AMR) as one of the ten most critical global threats to public health, the bacterium Neisseria gonorrhoeae has progressively developed resistance to many classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. "Today's acceptance of the zoliflodacin NDA marks significant progress toward delivering health care providers with a potential new oral treatment option for uncomplicated gonorrhea, including infections caused by drug-resistant strains," said David Altarac, M.D., Chief Medical Officer, Innoviva Specialty Therapeutics. "We look forward to working closely with the FDA during its review and, if approved, we are committed to expediting the availability of zoliflodacin to patients in the U.S." Recent reports (The Lancet Infectious Diseases) of emergent ceftriaxone-resistant infections have heightened the urgency for new antibiotics. Effective treatment options are essential to reducing the burden of disease for individuals and preventing the spread of highly drug-resistant gonorrhea globally. If left untreated, gonorrhea can also cause infertility in women, life-threatening ectopic pregnancies, and pelvic inflammatory disease.2 The FDA's acceptance of the zoliflodacin NDA is based on the totality of data collected from several clinical trials as part of an innovative public-private partnership with GARDP. These trials include a pivotal Phase 3 clinical trial which demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection of a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of ceftriaxone followed by 1 week of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. "This important milestone demonstrates the crucial role that public-private partnerships can play in tackling the escalating global antimicrobial resistance crisis," said Dr. Manica Balasegaram, Executive Director, Global Antibiotic Research Development Partnership (GARDP). "If zoliflodacin is approved, this collaboration paves the way for millions of people across the world to get access to a potentially powerful new drug to treat multidrug-resistant gonorrhea." Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In vitro studies have demonstrated its activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. This investigational antibacterial is administered in a single, oral dose, simplifying treatment by providing a convenient option for patients unable to receive an intramuscular injection. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Innoviva Specialty Therapeutics, Inc., anticipates that the NDA review will proceed according to the standard process for drugs with this designation. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. On December 14, 2024, Innoviva entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to View source version on Contacts Media Contacts:Innoviva Specialty TherapeuticsDavid +1.908.421.5971GARDPDuncan Graham-Rowedgrahamrowe@ +44 7966 413623 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Fully insured medical claims analysis shows significant cost savings and 2.4x ROI for Hinge Health populations
Methodology validated by leading global benefits consultant SAN FRANCISCO, June 10, 2025--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced results from a medical claims analysis revealing an average $2,343 savings per member per year on care for chronic musculoskeletal (MSK) conditions and a 2.4x return on investment (ROI) for fully insured health plan members using its digital MSK platform. The methodology of the medical claims analysis of 4,788 health plan members was validated by Gallagher, a leading global insurance brokerage, risk management, and consulting firm. MSK costs remain one of the top drivers of health costs, placing increasing pressure on benefits leaders to ensure programs deliver value and cost-efficiency. The medical claims analysis examined the impact of Hinge Health on medical care costs and utilization among participants enrolled in fully insured health plans. The study found meaningful cost savings from reduced utilization across a spectrum of healthcare services, including injections and physical or occupational therapy, with the majority of claims reductions (44%) coming from avoided surgeries. "Employers today face tremendous pressure to contain costs without sacrificing the quality of employee benefits," said Jim Pursley, President, Hinge Health. "This analysis proves that health plans can deliver better health outcomes and an outstanding member experience with Hinge Health, while driving down healthcare spend." The analysis leveraged a claims database that represented more than 100 million commercially insured lives from January 1, 2017 to September 30, 2023. To estimate savings, the study compared medical cost and utilization between Hinge Health participants and a matched control group between a baseline year and the 12 months after Hinge Health members started care. This new analysis builds upon previous cost analysis studies that demonstrate the cost-savings that Hinge Health provides. Hinge Health's digital MSK platform has consistently shown a financial benefit of more than 2x ROI across industries and participant demographics through multiple third-party validations, including a multi-employer study and Medicare population evaluation. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California. View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
